Lixte Biotechnology Holdings, Inc. (LIXTW)
US — Healthcare Sector
Automate Your Wheel Strategy on LIXTW
With Tiblio's Option Bot, you can configure your own wheel strategy including LIXTW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LIXTW
- Rev/Share 0.0
- Book/Share 0.469
- PB 3.0064
- Debt/Equity 0.0
- CurrentRatio 3.8995
- ROIC -4.1535
- MktCap 3784539.0
- FreeCF/Share -1.1911
- PFCF -1.2856
- PE -1.0483
- Debt/Assets 0.0
- DivYield 0
- ROE -2.3747
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Lixte Biotechnology Holdings, Inc. (LIXTW)
- IPO Date 2020-11-27
- Website https://lixte.com
- Industry Biotechnology
- CEO Mr. Bastiaan van der Baan M.Sc.
- Employees 2
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.